The research showed that the 'prime boost' approach is compatible with co-administration of vectors encoding for HIV and HCV antigens (molecules capable of inducing an immune response).
13 April 2016 | EASL press release
Monkeys in the study did not show signs of persistent infection until they were exposed to nearly 70,000 times the average amount of virus an infected man passes to a partner during intercourse.
12 April 2016 | UPI.com
UNITAID has published a report that asks how best to separate the costs of research and development for vaccines, medicines and diagnostics from their prices – a concept known as “delinkage”.
02 March 2016 | UNITAID
Kenneth Mayer: Despite our great progress, we require better tools to fight AIDS. That is why there is so much excitement around this year’s annual Conference on Retroviruses and Opportunistic Infections, which will convene in Boston Feb. 22-25. We are going to learn more about two emerging tools to control the HIV/AIDS epidemic: prevention medicines that are easy to use and protect those who are HIV negative from infection, and advances in vaccine research.
21 February 2016 | Boston Globe
Initiated and organised entirely by the community of people living with and at risk for HIV, the second European HIV Prevention Summit brought together representatives of civil society, the pharmaceutical industry, researchers and academia in Brussels between 29 and 31 January. In addition to a thorough examination of PrEP (pre-exposure prophylaxis), the summit discussed the latest developments in the research fields of vaccines, rectal and vaginal microbicides and antibodies and their utility in HIV prevention.
03 February 2016 | EATG
It isn’t too out of the ordinary for Gates Foundation grant awards to soar into the eight- and even nine-figure range. So, its $20 million grant to Moderna Therapeutics to support its continuing development of a novel but promising HIV prevention therapy isn’t particularly extraordinary. But what is unusual...is that the total potential commitment from the foundation could reach upwards of $100 million—around 70 percent of the Gates Foundation’s HIV/AIDS grants for all of last year.
27 January 2016 | Inside Philanthropy
The European Commission has granted over 22 million Euros to the European HIV Vaccine Alliance (EHVA) to develop a multidisciplinary platform to evaluate novel preventive and therapeutic vaccines. The grant is supplemented with additional 6 million Euros from the Swiss government for the Swiss project partners.
27 January 2016 | Eurekalert Inf Dis
Human trials of more than 100 different AIDS vaccines have taken place since researchers proved in 1984 that HIV caused the disease. Robert Gallo, whose U.S. National Cancer Institute laboratory published the four landmark papers in Science that convinced the world of the link between this recently discovered retrovirus and the growing epidemic, has closely monitored—and often sharply critiqued—the AIDS vaccine search since it began. But Gallo, who now runs the Institute of Human Virology (IHV) in Baltimore, Maryland, has always been a spectator—until today.
14 October 2015 | Science Insider
HIV Prevention Research & Development Funding Trends 2000–2014: Investment Priorities To Fund Innovation In An Evolving Global Health And Development Landscape is the 11th annual report by the Working Group, a collaboration among AVAC, UNAIDS, and the International AIDS Vaccine Initiative (IAVI). The report summarizes investment in HIV prevention research across eight prevention options, as well as HSV-2 vaccine and HIV cure and therapeutic vaccine R&D.
19 July 2015 | AVAC
The massive challenge of finding an HIV vaccine has unleashed stunning creativity in laboratories all over the world. While we work toward the long-term goal of a vaccine, we are also pulling in partners from many sectors to improve prevention, treatment, and access to options in the short term.
13 July 2015 | Devex